New study aims to unlock secrets of rare cholesterol diseases
NCT ID NCT05047354
First seen Jun 25, 2026 · Last updated Aug 06, 2026 · Updated 5 times
Summary
This natural history study is observing up to 250 people with Smith-Lemli-Opitz syndrome and related cholesterol disorders, as well as their relatives. Researchers will track symptoms, development, and lab results over several years to find better ways to measure disease progression. No treatment is being tested, but the data could help design future clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could identify ways to measure disease progression, helping design future treatments for these rare cholesterol disorders.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly benefit participants and may take years to yield useful results.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTLEY-BIXLER SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Newborn screening study aims to catch rare diseases at birth
- Posture fix? alexander technique tested in teens
- Rare genetic disorder studied for clues to better care
- Scientists investigate metabolism in kids with rare genetic syndrome
- Light-Based brain cap could replace radiation scans for kids
- Scientists dive into rare cholesterol disorders to uncover clues